ATOS — ATOSSA THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1488039 ·
Last close
$2.46
Market Cap
$21.18M
52W High
$6.28
52W Low
$2.45
ADV30
118,383
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,870,000 | -9,589,000 | 37,943,000 | 31,718,000 | 7,457,000 |
| Dec 2025 | 0 | — | -11,436,000 | -10,937,000 | 47,608,000 | 41,299,000 | 8,255,000 |
| Sep 2025 | 0 | — | -9,251,000 | -8,692,000 | 58,012,000 | 51,845,000 | 8,225,000 |
| Jun 2025 | 0 | — | -9,040,000 | -8,423,000 | 64,515,000 | 57,857,000 | 6,820,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-29,762,000
Investing CF
$-23,000
Financing CF
$0
CapEx
$-33,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-3.75
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-246,562,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-37,141,000
Pretax Income TTM
$-34,770,000
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -37,141,000 | -34,770,000 | 47,608,000 | 8,255,000 | — | -29,762,000 |
| Dec 2024 | 0 | -27,621,000 | -25,504,000 | 76,444,000 | 4,967,000 | — | -21,030,000 |
| Dec 2023 | 0 | -31,377,000 | -30,094,000 | 96,252,000 | 5,236,000 | — | -20,941,000 |
| Dec 2022 | 0 | -27,691,000 | -26,960,000 | 123,532,000 | 5,568,000 | — | -20,760,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.44
Max Pain — expiry 2026-07-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.50 · spot: $2.35 · call volume: 18 · put volume: 2
Expected Move to 2026-07-17:
±$0.60
(25.53%) —
implied range
$1.75 –
$2.95
· ATM straddle on $2.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $21.10M | $13.40 | — |
| VYNE | VYNE Therapeutics Inc. | $21.65M | $0.65 | — |
| CELU | Celularity Inc | $20.64M | $0.71 | — |
| OTLC | Oncotelic Therapeutics, Inc. | $22.22M | $0.05 | — |
| CRVO | CervoMed Inc. | $22.68M | $2.45 | — |
News headlines (Yahoo Finance, 1h cache)
Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-12 21:30 · Yahoo
Top Midday Decliners
2026-06-11 17:47 · Yahoo
Atossa Therapeutics Announces Registered Direct Offering of up to $16.5 Million in Gross Proceeds
2026-06-11 12:00 · Yahoo
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment
2026-06-10 16:51 · Yahoo
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics
2026-06-01 09:05 · Yahoo
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial
2026-05-27 12:30 · Yahoo
Atos Selected by Viasat to Modernize Global Digital Workplace Operations
2026-05-19 15:09 · Yahoo
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer
2026-05-14 12:30 · Yahoo
ATOS: Initiating Coverage of Atossa Therapeutics; Endoxifen’s Expanding Opportunity from Oncology to Orphan Disease
2026-05-13 07:00 · Yahoo
Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update
2026-05-08 12:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.